MCM
GSK icon

Marathon Capital Management’s GSK GSK Stock Holding History

Marathon Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-81,793
Closed -$4.45M – 158
2022
Q2 		$4.45M Sell
81,793
-1,988
-2% -$110K 1.44% 13
2022
Q1 		$4.56M Sell
83,781
-335
-0.4% -$18.2K 1.31% 18
2021
Q4 		$4.64M Sell
84,116
-605
-0.7% -$31.5K 1.09% 15
2021
Q3 		$4.05M Buy
84,721
+91
+0.1% +$4.57K 0.92% 19
2021
Q2 		$4.21M Sell
84,630
-252
-0.3% -$12.1K 0.98% 18
2021
Q1 		$3.79M Buy
84,882
+4,147
+5% +$188K 1% 21
2020
Q4 		$3.71M Sell
80,735
-9,993
-11% -$459K 1.09% 17
2020
Q3 		$4.27M Sell
90,728
-3,422
-4% -$171K 1.55% 5
2020
Q2 		$4.8M Buy
94,150
+33,840
+56% +$1.74M 1.84% 3
2020
Q1 		$2.86M Sell
60,310
-196
-0.3% -$10.5K 1.31% 9
2019
Q4 		$3.55M Buy
60,506
+3,708
+7% +$206K 1.21% 7
2019
Q3 		$3.03M Buy
56,798
+84
+0.1% +$4.32K 1.22% 7
2019
Q2 		$2.84M Sell
56,714
-524
-0.9% -$26.3K 1.16% 9
2019
Q1 		$2.99M Sell
57,238
-835
-1% -$41.7K 1.34% 6
2018
Q4 		$2.77M Sell
58,073
-4,660
-7% -$229K 1.38% 5
2018
Q3 		$3.15M Sell
62,733
-1,012
-2% -$51.4K 1.22% 8
2018
Q2 		$3.21M Buy
63,745
+270
+0.4% +$13.6K 1.21% 4
2018
Q1 		$3.1M Buy
63,475
+8,248
+15% +$384K 1.21% 7
2017
Q4 		$2.45M Sell
55,227
-281
-0.5% -$13K 0.96% 17
2017
Q3 		$2.82M Buy
55,508
+20
+0% +$1.01K 1.19% 13
2017
Q2 		$2.99M Buy
55,488
+360
+0.7% +$19.2K 1.41% 11
2017
Q1 		$2.9M Buy
55,128
+316
+0.6% +$16K 1.44% 11
2016
Q4 		$2.64M Buy
54,812
+43,936
+404% +$2.17M 1.26% 10
2016
Q3 		$586K Buy
+10,876
New +$596K 0.29% 45

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Marathon Capital Management's GSK Position: Q3 2022 in Review

Marathon Capital Management sold out of GSK (GSK) in Q3 2022, closing a stake of 81,793 shares — an estimated $4.45M sold.

Marathon Capital Management first reported a position in GSK in Q3 2016 and held it in 24 quarters. The position peaked at $4.8M in Q2 2020. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

  • Marathon Capital Management reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
  • Marathon Capital Management sold 81,793 GSK shares in Q3 2022, an estimated $4.45M.
  • Marathon Capital Management first reported a position in GSK in Q3 2016 and held it in 24 quarters.
  • Marathon Capital Management's GSK position peaked at $4.8M in Q2 2020.
  • 742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Marathon Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.